HBM7004 can now enter clinical development in both China and the United States after NMPA and FDA IND clearances, putting Harbour BioMed’s B7H4-dependent T-cell engager into its first human test.
Harbour BioMed has signed a global strategic collaboration and license agreement with Bristol Myers Squibb to discover and develop next-generation multispecific antibodies. The deal could be worth over $1.1 billion across upfront payments, milestones, and royalties. It also signals growing interest in platforms capable of generating novel immunotherapies for complex diseases. The announcement is not